Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SEPN vs DYN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SEPN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–5 Matrix Metrics)

SEPN Overall Winner 6-Pillar Tally: SEPN 3 – 2 DYN (1 Tie) Matrix Metrics: SEPN 5 – 5 DYN

As of Nov 20, 2026, Septerna, Inc. (SEPN) is the stronger overall head-to-head candidate over Dyne Therapeutics, Inc. (DYN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). SEPN carries a Unified Composite Score of 44.8/100 (HOLD) at $38.61 (107.5x Forward P/E, -76.2% operating margin), whereas DYN carries 39.9/100 (SELL) at $15.50 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: SEPN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 39.7); meanwhile DYN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SEPN vs DYN
SEPN NASDAQ Head-to-Head Winner
Septerna, Inc. Common Stock
Pharmaceutical Preparations
$38.61
-1.51% 1D
Market Cap $1.9B
TTM Revenue $96M
Forward P/E 107.5x
Beta / 30D Vol 0.96β · 75% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 28.0 Fund 43.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 40
RSI-14: 39.7 · SMA20: $44.25 · SMA50: $40.68
DYN NASDAQ
Dyne Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$15.50
-3.31% 1D
Market Cap $3.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.55β · 55% Vol
Unified Composite Score
39.9 / 100 SELL
Tech 25.0 Fund 48.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.0%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $17.08 · SMA50: $16.55

6-Pillar Scorecard Institutional Category Breakdown (SEPN 3 – 2 DYN)

Columns: Metric · SEPN · DYN
1. Valuation Multiples SEPN
Forward P/E 107.5x N/M
Trailing P/E 107.5x N/M
PEG Ratio N/M 0.19x
EV / Revenue 19.4x N/M
2. Growth & Scale DYN
Revenue Growth (YoY) -12.2% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $96M N/A
Market Cap $1.9B $3.0B
3. Profitability & Quality DYN
Gross Margin 100.0% N/A
Operating Margin -76.2% 0.0%
Net Profit Margin -61.3% 0.0%
Return on Equity (ROE) -14.4% -74.6%
4. Balance Sheet & Cash Flow SEPN
Cash Generation (TTM) -$72M EBITDA -$569M
Cash Flow Margin -74.5% EBITDA Mgn N/A
Net Cash / Leverage $9.03 Book/Sh · -14.4% ROE $694M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SEPN
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 73.8% (7th %ile) 58.2% (9th %ile)
Put/Call OI Skew N/A 0.06x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SEPN (5) vs DYN (5)
Institutional Metric SEPN DYN Criterion Row Edge
Market Capitalization
Scale
$1.9B $3.0B Larger Scale DYN
Trailing P/E Ratio
Valuation
107.5x N/M Lower Multiple SEPN
Forward P/E Ratio
Valuation
107.5x N/M Lower Multiple SEPN
Revenue Growth (YoY)
Growth
-12.2% +0.0% Higher Growth DYN
Operating Margin (TTM)
Profitability
-76.2% 0.0% Higher Margin DYN
Net Profit Margin
Profitability
-61.3% 0.0% Higher Margin DYN
Return on Equity (ROE)
Capital Efficiency
-14.4% -74.6% Higher ROE SEPN
52-Week Range Position
Momentum
54% ($22–$53) 11% ($14–$27) Stronger Trend SEPN
Beta / 30D Volatility
Risk Regime
0.96β · 75% Vol 1.55β · 55% Vol Lower Realized Risk DYN
Unified Institutional Score
Composite Signal
44.8 / 100 (HOLD) 39.9 / 100 (SELL) Higher Composite SEPN
Trailing 12M Revenue (USD)
Operating Scale
$96M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 19.4x EV/Rev 0.19x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$72M EBITDA ($9.03 Book/Sh · -14.4% ROE) -$569M ($694M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DYN +3.84 pp
SEPN: -5.55% · DYN: -1.71%
3M Horizon SEPN +35.65 pp
SEPN: -4.71% · DYN: -40.36%
6M Horizon SEPN +46.91 pp
SEPN: +36.14% · DYN: -10.77%
1Y Horizon SEPN +91.9 pp
SEPN: +67.14% · DYN: -24.76%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SEPN vs DYN. Trailing 12-month operating profitability (SEPN -76.2% vs DYN 0.0%) and valuation multiples (SEPN 107.5x vs DYN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SEPN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$96M
Gross Margin100.0%
Op. Margin-76.2%
ROE / Fwd P/E-14.4% · 107.5x
DYN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-74.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SEPN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 73.8%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SEPN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DYN BREAKDOWN
72d in phase · OBV DISTRIBUTION
Current IV 58.2%
IV Percentile 9th %ile
Put/Call OI Skew 0.06x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact DYN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $15.87 · IV 56.7%

DYN Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,587)

Compare $1,587 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 56.7% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $16 / $17.5 Bull Call Spread

Buy 2x $16C · Sell 2x $17.5C · 30d

Net Entry $200 Debit
T+5d @ +5% Move +$24 (+12%)
Max Risk / Buffer $200 Capped
5d Edge & Liquidity 0.5x R:R · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $16 / $15 Bear Put Spread

Buy 2x $16P · Sell 2x $15P · 30d

Net Entry $136 Debit
T+5d @ -5% Drop +$22 (+16%)
Max Risk / Buffer $136 Capped
5d Edge & Liquidity 0.6x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SEPN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and -76.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DYN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SEPN vs DYN Key Questions & Quantitative Answers

As of Nov 20, 2026, Septerna, Inc. (SEPN) is the stronger overall head-to-head candidate over Dyne Therapeutics, Inc. (DYN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). SEPN carries a Unified Composite Score of 44.8/100 (HOLD) at $38.61 (107.5x Forward P/E, -76.2% operating margin), whereas DYN carries 39.9/100 (SELL) at $15.50 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: SEPN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 39.7); meanwhile DYN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DYN leads the Growth & Scale pillar: SEPN posts -12.2% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (100.0% gross margin, -76.2% operating margin), compared with DYN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SEPN generates $96M in USD-normalized revenue versus N/A for DYN. In operating R&D and SG&A reinvestment, SEPN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DYN.

SEPN screens cheaper on headline valuation multiples. SEPN trades at 107.5x Forward P/E, 107.5x Trailing P/E, N/M PEG, and 19.4x EV/Revenue (-74.5% EBITDA margin), whereas DYN trades at N/M Forward P/E, N/M Trailing P/E, 0.19x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SEPN (-14.4% ROE) versus DYN (-74.6% ROE) capital efficiency.

In options market volatility and institutional positioning, SEPN carries 73.8% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.96β · 75% Vol realized risk). By comparison, DYN carries 58.2% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.55β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.